Cambrex — Merger or Acquisition (July 2018)
11 slides from Cambrex's merger presentation, Jul 23, 2018
Slide 1: Cambrex to Acquire Halo Pharma
Cambrex to Acquire Halo Pharma July 23, 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma (“Halo”) and expected benefits therefrom (including revenue and earnings expectations), future financial and operating results, outlook, growth, prospects, business strategies, future market position,
Slide 3: Transaction Overview
Transaction Overview $425 million total cash consideration To be funded with balance sheet cash and borrowings on $500 million senior credit facility Halo had Revenue and Adjusted EBITDA of $105 million* and $27 million, respectively for the 12 months ended 06/30/18 Enhances top-line revenue growth
Slide 4: Halo Pharma Overview
Halo Pharma Overview Broad dosage form manufacturing capabilities Oral solids, liquids and sterile ointments and gels Specialty offerings include modified release, pediatric dosage forms and oral dissolving tablets, among others Focus on complex dosage forms Differentiated drug delivery, controlled
Slide 5: Strategic Rationale
Strategic Rationale Expands addressable market and creates new avenue for growth within the large, fragmented and growing market for outsourced finished dosage form contract development and manufacturing Diversifies business, expands customer base and broadens molecule funnel Extends capabilities th
Slide 6: Provides Entry into the Finished Dose CDMO Market
Provides Entry into the Finished Dose CDMO Market Cambrex will participate in 2 large and growing markets with increasing outsourcing penetration Finished Dosage Form [2] Small Molecule API [1] CDMO Small Molecule API Total Market Size $50-60B CDMO Finished Dosage Form Total Market Size $55-60B 50-6
Slide 7: Creates Leading Small Molecule CDMO with End-to-End Capabilities
Creates Leading Small Molecule CDMO with End-to-End Capabilities Drug Development Commercialization Clinical Phase I Clinical Phase II Clinical Phase III Launch Phase IV Generics Preclinical Development File IND File NDA Cambrex (High Point, NC, US) Cambrex (Charles City, IA, US) Cambrex (Karlskoga,
Slide 8: Efficient Finished Dose Manufacturing Network
Efficient Finished Dose Manufacturing Network 167,000 ft2 (21 Acres) Controlled substance manufacturing (DEA Schedule I-V) Large vault capacity for additional narcotics storage Capabilities include analytical method development, formulation, transfers, release, microbiologic testing, manufacturing a
Slide 9: Accelerates Growth
Accelerates Growth Halo acquisition provides immediate growth with long-term upside Revised guidance for 2018 will be provided post-closing in our Q3 Earnings Call Expected to be accretive to adjusted EPS in 2019 Adjusted EBITDA is a non-GAAP financial measure. The reconciliation to the most directl
Slide 10: Summary
Extends customer offering beyond APIs and forward integrates business into new revenue streams in large, growing finished dosage form outsourcing market Provides high quality, complex finished dose manufacturing platform Diversifies business and enhances customer base and product and service offerin
Slide 11: Cambrex to Acquire Halo Pharmaceutical
Cambrex to Acquire Halo Pharmaceutical July 23, 2018